Cellsway, established in 2020, focuses on development of microfluidics and lab-on-a-chip systems for biomedical applications. With the vision of becoming a global player in the field of biomedical microsystems technology by introducing innovative solutions to unmet needs; the company’s mission is to convert the know-how and the patented cutting-edge technology into commercial products to set the gold standard for diagnosis and management of cancer.
The core product of the company is a liquid biopsy platform which uses a simple blood sample for cancer diagnostics and cancer research. Cellsway’s liquid biopsy platform will exploit the potential of Circulating Tumour Cells (CTCs) by integrating patent-pending microfluidics for CTCs enrichment with a number of proprietary downstream assays. The platform enables identification and characterization of CTCs, thus providing clinically actionable data for clinicians in diagnosis, therapy selection and cancer monitoring.